Sutro Biopharma to Report Q4 2025 Earnings

Biotech firm scheduled to release quarterly results before market open on Thursday

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Sutro Biopharma (NASDAQ:STRO), a clinical-stage biopharmaceutical company focused on oncology and immunology, is set to release its Q4 2025 earnings results before the market opens on Thursday, March 12, 2026.

Why it matters

As a publicly traded biotech company, Sutro Biopharma's quarterly earnings reports provide important updates on the firm's financial performance and pipeline progress, which can impact investor sentiment and the stock price.

The details

Analysts expect Sutro Biopharma to report a loss of $4.66 per share and revenue of $9.26 million for the fourth quarter of 2025. The company will host an earnings call on Friday, March 27, 2026 at 4:00 PM ET to discuss the results.

  • Sutro Biopharma will release Q4 2025 earnings before the market opens on Thursday, March 12, 2026.
  • The company will host an earnings call on Friday, March 27, 2026 at 4:00 PM ET.

The players

Sutro Biopharma

A clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology.

Got photos? Submit your photos here. ›

The takeaway

Sutro Biopharma's upcoming earnings report will provide investors with an update on the company's financial performance and pipeline progress as it continues to advance its immuno-oncology candidates through clinical development.